Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.3B
80M shares
52-week range
$29.46 – $60.91
34% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
P/S (TTM)
5.9
EV / FCF (TTM)
18.4
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
www.veracyte.comNo one on the platform currently holds VCYT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 223,500 | $7.2M |
| Bridgewater Associatesas of 2026-03-31 | 91,590 | $3.0M |
No one on the platform has traded VCYT yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.3% | — | — | — | ||
| Rev. Growth % | 16.0% | 34.5% | ||||
| Profit Margin % | 12.8% | -9.8% | -20.6% | |||
| Free Cash Flow Margin % | 24.5% | 6.2% | -8.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -0.7% on the P/E track.
At today's price, your expected annual return is +4.5% on the P/E track.
At today's price, your expected annual return is +8.9% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $594M | +16.0% | $1.91 | $1.86–$1.93 | 21.0× | 7 |
| 2027 | $660M | +11.2% | $1.96 | $1.93–$1.98 | 20.5× | 7 |
| 2028 | $732M | +10.8% | $2.08 | $1.53–$2.54 | 19.3× | 5 |
| 2029 | $845M | +15.4% | $2.18 | $2.11–$2.24 | 18.4× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.41 | $0.54 | +31.6% |
| 2026-05-05 | $0.34 | $0.52 | +52.9% |
| 2026-02-25 | $0.41 | $0.53 | +29.8% |
| 2025-11-04 | $0.32 | $0.51 | +59.4% |
| 2025-08-06 | $0.31 | $0.44 | +41.9% |
| 2025-05-07 | $0.12 | $0.31 | +151.8% |
| 2025-02-24 | $0.10 | $0.07 | -30.0% |
| 2024-11-06 | $0.03 |
| $0.19 |
| +533.3% |
| $3.6B |
| — |
| IRONDisc Medicine, Inc. | $67.30 | -2.35% | $2.6B | — |
| KNSAKiniksa Pharmaceuticals International, plc | $75.15 | -1.87% | $5.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
@arribaStocktrading @Wax_Bean_futures oh btw I started a position in $VCYT today. Thanks for the recommendation. Certainly looks interesting but valuation is not like super attractive. I’ll wait and see if there are any better opportunities to double down
View on StockTwits ↗
$VCYT https://anachart.com/wp-content/uploads/2026/09/1789473676_soc-img.jpg
View on StockTwits ↗
$VCYT acquired Convergent Genomics for $150M cash plus up to $30M in milestones, adding UroAmp, a urine tumor DNA test for bladder cancer. https://notreload.xyz/xy/veracyte-buys-convergent-adds-urine-test-for-bladder-cancer/
View on StockTwits ↗
$VCYT 💪 Now making higher lows on top of $40 ~ tiny gap from $33 to $39 that would be ideal for entries
View on StockTwits ↗
$VCYT 200d approaching. Not lookin so good. No position but still on W/L for another long swing.
View on StockTwits ↗
@Richk515 I don’t see the downside to taking a few nibbles. It’s had quite the run up, which is part of the reason for the sell off. It is very hard to generate cash in this space, especially as a smaller company, but $VCYT seems to do it well-so it supports a high valuation multiples vs. peers. Less of a downside risk at this price…
View on StockTwits ↗
$VCYT For the few that follow this one. I have watched this stock for years. Been awhile since my last position, but never off of w/l. Setting alert at 200d for further evaluation. HC having difficulty today.
View on StockTwits ↗
$RDDT $VCYT $GDDY $SYK AFTER-HOURS MOVERS: Currently Higher After Earnings: - Cohu (COHU) up 17.8% - Ryan Specialty Holdings (RYAN) up 13.4% - Monolithic Power Systems (MPWR) up 10.7% - Amazon (AMZN) up 9.5% - DexCom (DXCM) up 7.4% - Guardant Health (GH) up 6.7% - SPX Technologies (SPXC) up 8.4% - Merit Medical Systems (MMSI) up 4.4% Currently Lower After Earnings: - MasTec (MTZ) down 14.0% - Roblox (RBLX) down 14.0% - Reddit (RDDT) down 10.4% - Veracyte (VCYT) down 11.3% - GoDaddy (GDDY) down 8.4% - Stryker (SYK) down 7.7% - Apple (AAPL) down 6.3% - Coinbase Global (COIN) down 5.1%. - Corteva (CTVA) down 1.7%
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-7-30-veracyte-inc-stock/ $VCYT Veracyte Earnings Transcript
View on StockTwits ↗
$VCYT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.32 up 3300.00% YoY • Reported revenue of $150.32M up 15.49% YoY • Veracyte is raising 2026 total revenue guidance to $590 million to $596 million, or 14% to 15% growth, and testing revenue guidance to $576 million to $582 million for the year.
View on StockTwits ↗
$VCYT just need to break $60.91 and its off to the races
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.